Coronovirus vaccine is highly effective against B1.617.2 variant, revealed by a Study in UK: A new study was conducted by some health officials in UK. It shocked everyone with its results. For the first time, it has revealed that the two doses of coronavirus vaccines are highly effective against the B1.617.2 variant i.e. the variant which was primarily reported in Maharashtra, India. It has also been referred as a double mutation variant throughout the world.
Coronavirus Vaccines effectiveness against B1.617.2 Variant:
As said by PHE (Public Health England) “The Pfizer or BioNTech vaccine was about 88 per cent effective against symptomatic COVID-19 from the B1.617.2 variant of concern (VOC) two weeks after the second dose, the Oxford/AstraZeneca vaccine was 60 per cent effective against symptomatic disease from the B1.617.2 VOC.”
However after a single dose of jab of vaccine, it was not much effective against VOC found in India. It’s effectiveness was 33% only.
As per Matt Hancock, the health secretary of UK, “This new evidence is groundbreaking – and proves just how valuable our COVID-19 vaccination programme is in protecting the people we love,”.
He further said that “It’s clear how important the second dose is to secure the strongest possible protection against COVID-19 and its variants – and I urge everyone to book in their jab when offered, I’m increasingly confident we”re on track for the roadmap because this data shows the vaccine after two doses works just as effectively, and we all know that the vaccine is our way out of this”
As per the reports from analysis, the effectiveness of vaccine after two doses of jab is same in B1.617.2 variant as in the variant which is currenty present in UK. PHE (Public Health England) expects that the results will be more better in future and will be more effective against hospitalizations and deaths.
PHE also revealed that the difference in effectiveness between the vaccines after two doses could be explained by the fact that the second doses of AstraZeneca was rolled out a bit later than the Pfizer vaccine. The other data on antibody profiles showed that it usually takes longer to reach maximum effectiveness with the AstraZeneca vaccine.
A statement was also given by the vaccine deployment minister of UK, Nadhim Zahavi that “Today’s data is astounding and a true reflection of just how important it is to get both your jabs when offered. I encourage all those offered an appointment to get their jab booked in as soon as possible and take full advantage of the high levels of protection the vaccines bring”
PHE believes that since there are very less cases and insufficient follow up periods, it is taking longer for them to estimate the effectiveness of coronavirus vaccine against the B1.617.2 variant, but they believe that they will definitely be able to evaluate this in the future. They estimate this not only in the case of variant primarily reported in India but also in the case of other variants which are being reported from different parts of world.